Clinical Trial

Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-31 -> 2027-07-31 2026-04-14
minor Completion pushed: 2026-12-31 -> 2027-12-31 2026-04-14
Trial Details
NCT Number NCT05025605
Lead Sponsor BioXcel Therapeutics Inc
Collaborators: ProPharma Group
Conditions Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I, Bipolar Disorder II
Enrollment 140 participants
Start Date 2021-08-27
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-11